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Summary
Within the past several years, the relation between diet and
health has been accepted by the mainstream nutrition com-
munity and in this connection interest in the physiological
role of bioactive compounds present in plants has dramatical-
ly increased over the last decade.
The phytoestrogens are bioactive molecules present as nutri-
tional constituents of widely consumed vegetables. Their name
derives from the fact that they are able to bind to estrogen re-
ceptors and to induce an estrogenic/antiestrogenic response
in target tissues. Natural estrogens are involved in a multiplici-
ty of programmed events in target tissues as uterus, breast, pi-
tuitary gland and hormone responsive tumors. Phytoestrogens
are present in many human foodstuffs including fruits (plum,
pear, apple grape berries, …), vegetables (beans, sprouts, cab-
bage, spinach, soybeans, grains, hops, garlic, onion,…), wine,
tea, and they have been identified in a number of botanical di-
etary supplements. They include a wide variety of structurally
different compounds such as isoflavones, mainly found in soy,
lignans found in grains, stilbenes found in the skin of grapes.
Other less investigated compounds include flavones, flavans,
isoflavanes and coumestans. The estrogenic or antiestrogenic
activity of any chemicals depends on the ability of the com-
pound to interact with the ERs (ERα, ERβ).
This article reported the knowledge about the activity of phy-
toestrogens from a pharmacological point of view for their es-
trogenicity or antiestrogenicity.
KEY WORDS: phytoestrogens, nutrition, bioactive compounds, soy, bone
health.
Introduction
Within the past several years, the relation between diet and
health has been accepted by the mainstream nutrition commu-
nity, and in this connection interest in the physiological role of
bioactive compounds present in plants has dramatically in-
creased over the last decade. As a complex mixture of chemi-
cals, foods provide essential nutrients, requisite calories, and
other physiologically active constituents that may be useful for
life and health. A new paradigm for “optimal nutrition” may be
evolving that would identify physiologically active components
that contribute to diseases prevention. In thus functional foods
concept is unifying the medical, nutritional and food sciences
(Fig. 1). Collectively, plants contain several different families of
natural bioactive products among which are compounds with
weak estrogenic or antiestrogenic activity toward mammals. Of
particular interest, in relation to human health, are these plant
derived estrogens, or phytoestrogens, which embody several
groups of non-steroidal estrogens widely distributed within the
plant kingdom. Although in vitro and animal studies provide
preliminary plausible mechanisms to explain how phytoestro-
gens act, the applications of diets rich in such compounds and
their consequent biological effects still need to be fully exam-
ined, tested and confirmed through traditional scientific experi-
mental pathway (Table I). Phytoestrogens are strikingly similar
in chemical structure to the mammalian estrogen, estradiol,
and bind to estrogen receptors (ERs) with the preference for
ERβ (1). This suggests that these compounds may exert tissue
specific effects, beside other non receptor mediated biological
activities, as antioxidant capacity and antiproliferative/antian-
giogenic effects.
Natural estrogens are involved in a multiplicity of programmed
events in target tissues as uterus, breast, pituitary gland and
hormone responsive tumors. The initiation of estrogen action
by all of the estrogens is considered to be the same in each
target tissue. Estrogen firstly bind to the nuclear ER, then an
estrogenic ligand causes a conformational change that en-
courages dimerization and interaction with either specific
DNA sequences or a protein-protein interaction with AP-1 or
Sp1 sites in the promoter region of estrogen-responsive
genes (2). These events herald the biological effects of estro-
gen in the specific target tissue or tumor. A small percentage
(2-3%) of ERs are located on the cell membrane and con-
tribute to non genomic effects of estrogen (3). Two ERs are
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Figure 1 - Phytoestrogens scientific research area.
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currently known, ERα and ERβ. Although the two ERs can be
localized within the same cell, they vary in tissue distributions
and can have different effects on mixed agonist and antago-
nist molecules.
Phytoestrogens include a wide variety of structurally diverse
compounds such as isoflavones, mainly found in soy, lignans
found in grains, stilbenes found in the skin of grapes. Other
less investigated compounds include flavones, flavans, isofla-
vanes and coumestans (4). The estrogenic or antiestrogenic
activity of any chemicals depends on the ability of the com-
pound to interact with the ERs (ERα, ERβ).
The aim of this article is to describe the substances that, up to
date, has been validated from a pharmacological point of view
for their estrogenicity or antiestrogenicity.
Phytoestrogens rich foods
Phytoestrogens are present in many human foodstuffs includ-
ing fruits (plum, pear, apple grape berries…), vegetables
(beans, sprouts, cabbage, spinaches, soybeans, grains, hops,
garlic, onion, …), wine, tea, and have been identified in a num-
ber of botanical dietary supplements (Table II). Plants vary in-
tra- and inter-species in the types and concentrations of phy-
toestrogens due to variables in plant growth, soil, weather con-
ditions and the age of plant. Chemically phytoestrogens are
phenolic phytochemicals or polyphenols. These are the largest
category of phytochemicals and the most widely distributed in
the plant kingdom (5).
Polyphenols in plants show a multiple function, they act as an-
tioxidants (protection against UV light), exert a protective action
from insects, fungi, viruses and bacteria, and a visual attention-
pollinator attraction (they are responsible of plant and flower
colours) and they can also serve as feed-repellents and plant
hormone controllers.
The study on phytoestrogens started in the ‘50s when it was
realized that some plants derived substances could cause an
estrogenic effect. Sheep that were grazing on pastures con-
taining red clover had multiple fertility problems and it was
shown that the clover present in this pastures had high
amounts of isoflavones (6), in particular formononetin and
biochanin A. 
The phytoestrogens classification is controversial, anyway cur-
rently we can subdivide the phytoestrogens in four main class-
es: flavonoids (flavones and isoflavones), lignans, coumen-
stans and stilbenes (Table III).
Flavonoids
They are the largest group of plant phenols including more
than 4000 different compounds which are the most studied
phytochemicals. The basic flavonoid structure allows a multi-
tude of variations in chemical structure, giving rise to flavonols
(quercetin, kaempferol, myricetin), flavones (apigenin, luteolin),
flavanones (catechin, epicatechin), antocyanidins and
isoflavonoids (glycitein, genistein, daidzein) (7). An important
effect of flavonoids is the scavenging of oxygen-derived free
radicals. The major source of isoflavonoids in the diet is from
soy-based foods. The isoflavonoids from legumes, including
genistein and daidzein, are the most studied phytoestrogens.
They can exist as glycosides or as aglycones, the glucosides
being readily hydrolized in the gut as their aglycones. The agly-
cones are easily transported across intestinal epithelial cells.
Genistein has one-third the potency of estradiol when interacts
with ERα, and one thousandth of the potency of estradiol when
it interacts with ERβ as determined by expression of luciferase
reporter gene construct in kidney cells that have been cotrans-
fected with ERα and ERβ (8). Genistein may produce similar
effects to estradiol in several different tissues as breast, ovari-
an, endometria, prostate, vascular , bone tissue and cell lines
(9, 10). Furthermore, genistein induce also responses that are
not associated with the ER, as the inhibition of tyrosine kinase
and DNA topoisomerase (11). Such effect is produced even in
the presence of the antiestrogen revealing a non genomic ac-
tion that could explain a part of the difference between genis-
tein and estradiol.
In vitro experimental systems also showed that flavonoids pos-
sess anti-inflammatory, antiallergic, antiviral and anticarcino-
genic properties (12) and various of these molecules, notably
isoflavonoids, are identified as phytoestrogens being able to
bind estrogens receptors, and possess estrogenic or antiestro-
genic activities (13, 14).
Lignans
They are constituens of higher plants, such as whole grains,
legumes, vegetables and seeds with exceptionally high concen-
trations of lignans found in flaxseed. Although previously though
to be present only in higher plants, mammalian lignans have
been detected in the biological fluids of humans and animals.
The chemical structure of plant lignans is very different from that
of mammalian lignans and most of the changes occur in the
colon, liver and small intestine. Enterolactone and enterodiol are
124 Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 123-130
L. Bacciottini et al.
Table I - Research needed to clarify possible roles of phytoestrogens in health.
• Identify the specific types of phytoestrogens that provide health benefits.
• Characterize the sources, dietary or supplemental.
• Define the effective dose of phytoestrogens that provide protection against a specific symtom.
• Determine the concentration at which pharmacologic doses become toxicologic problem.
• Identify new mechanisms by which the phytoestrogens produce protective effects.
• Identify specific binding proteins.
• Identify specific metabolites.
• Determine the effects of phytoestrogens on cells differentiations.
• Establish the pharmacokinetiks of delivered doses.
• Identify the proportion of the population likely to respond positively to phytoestrogens.
• Examine more closely the dietary components relative to the diet as whole.
Modified from Bidlack WR and Wang W. In “Modern Nutrition in Health and Disease”. Eds. Shils ME et al. 1999, 1823-1833. 
metabolites of the plant lignans metairesinol e secoisolari-
ciresinol, respectively (15). A clinical study showed that the ex-
cretion of the lignans, enterodiol and enterolactone, was signifi-
cantly higher during a carotenoid (carrots and spinaches) and
cruciferous (broccoli and cauliflowers) vegetable diet, than dur-
ing a vegetable-free diet (16).
Coumestans
Legumes are the main source of coumestrol, the coumestan
showing the highest estrogenic activity, and low level of
coumestrol have been found also in brussel sprouts and
spinaches, while the highest concentrations are reported in
clover and in soybean sprouts.
Stilbenes
Recently, also the stilben resveratrol has been identified as a
phytoestrogen. Resveratrol is a natural compound produced by
some plants, such as grapevines, in response to injury. Peanuts
are rich in resveratrol too. Polygonium cuspidatum roots, which
have long been used in traditional oriental medicine, have been
identified as the major active source of stilben phytoalexins.
Trans resveratrol was firstly detected in grapevines in 1976 by
Langcake and Pryce, who found that this compound was synthe-
sized by leaf tissues in response to Botrytis cinerea fungal infec-
tion or exposure to ultraviolet light (17).
The biological activity of resveratrol was attested about fifteen
years ago by the health benefits obtained by orally adminis-
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Table II - Levels of isoflavones and lignans in various food sources. Values (in nanomoles per gram dry weight) were determined by isotope
dilution gas chromatography mass spectrometry with selected ion monitoring. Mazur W, Adlercreutz H. 1998, modified.
Plant species Genistein Daidzein Secoisolariciresinol Metairesinol
(Common name)
Soybean 993-3115 413-2205 < 1-8 < 1
Kidney bean < 1-19 < 1-2 2-4 < 1
American groundnut 4-30 < 1 < 1-2 < 1
Chicpea 3-8 < 1-8 < 1 < 0
Pea < 1 < 1 < 1 < 1
Lentil < 1 < 1 < 1 < 1
Kudzu root 467 7283 < 1 < 1
Flaxseed < 0 < 0 10-247 30
Sunflower seed < 1 < 6 < 2 17
Peanut < 2 < 1 < 8 < 1
Wheat bran < 1 < 1 < 3 < 0
Barley < 1 < 1 < 2 < 0
Rye bran < 0 < 4 < 4 < 5
Strawberry < 0 < 0 33 < 1
Cranberry < 0 < 0 29 < 0
Bluberry < 0 < 0 23 < 0
Rasberry < 0 < 0 < 4 < 0
Red cabbage < 1 < 1 < 4 < 1
Broccoli < 1 < 1 11 < 1
Garlic < 0 < 0 11 < 1
Zucchini < 0 < 0 23 < 1
Carrot < 0 < 0 10 < 1
Breetroot < 0 < 0 < 3 < 1
Black tea Trace Trace 73 12
Green tea Trace Trace 75 < 5
Table III - Main chemical categories of phytoestrogens.
Lignans Flavonols Coumestans Isoflavones Stilbenes
Enterolactone Quercetin Cumestrol Glycitein Resveratrol
Enterodiol Rutin Genistein
Daidzein
tered resveratrol. An experimental study suggested that an av-
erage drinker of wine may, in the long term, absorb a quantity
of resveratrol sufficient to explain the beneficial effect of red
wine on human health (18). Resveratrol possesses anticancer
properties, antioxidant activity and some observations have
challenged the protective effects of resveratrol against athero-
sclerosis then preventing cardiovascular diseases. As a phy-
toestrogen it may favourably influence several physiological
processes and given that resveratrol has a different structure,
also its mechanism of action might differ somewhat from that of
other flavonoids (17, 18).
Health beneficial effects of phytoestrogens
In the last two decades many clinical and epidemiological stud-
ies have been performed to test the health effects of foods and
supplements rich in phytoestrogens. A recent review summa-
rizes the main results from scientific studies (19). The effects of
phytoestrogens administration are evaluated on different clini-
cal endpoints as listed in Table IV.
Cardiovascular health
Estrogen may affect the vascular system both directly through
the ERs located on vascular tissue, and indirectly through alter-
ing the lipoprotein profile (20). Initial epidemiologic studies
showed that women taking hormone replace therapy (HRT)
were 50% less likely to experience severe cardiovascular dis-
ease (CVD) than women not assuming HRT (21). Lately, a
more comprehensive study performed by the Women’s Health
Initiative has demonstrated a significant increase in CVD in the
first year of HRT use, permaining is still elevated after 5 years
of continued use (22-24). There are several clinical studies that
have examined the effect of phytoestrogens on CVD.
Isoflavonoids or soy/soy proteins and flaxseed have the ability
to lower total cholesterol (25, 26), LDL cholesterol (25, 27) and
to raise HDL cholesterol (28, 29). On the contrary, other stud-
ies showed no effect of isoflavonoids derived from soy or red
clover on serum cholesterol levels or plasma lipids (30, 31). 
Although no clinical studies showed that resveratrol improves
cardiovascular function, the consumption of red wine has been
linked to the French Paradox, phenomenon observed in French
people who have a diet similar to the North American diet with
a significantly lower rate at CVD (32).
Cancer
There is a large body evidence coming from epidemiologic stud-
ies showing people who consume high amounts of isoflavonoids
in their diets have lower rates of occurrence of several cancers
including breast, prostate and colon cancer (33).
The protective effect of phytoestrogens on cancer may be due
to their role in lowering circulating levels of unconjugated sex
hormones. Estrogens mainly circulate as inactive conjugates of
sex hormones binding globulin (SHBG) or albumin (34). Dietary
supplementation with soy isoflavonoids or lignans produced an
increase of the levels of SGHBG in postmenopausal women,
lowering the serum levels of estradiol (35, 36). Furthermore,
higher intakes of soy products and flaxseeds produced a signif-
icant decrease of the urinary excretion of genotoxic estrogen
metabolites (37). Moreover, the role of phytoestrogens in pre-
venting cancer in women may be related to changes in men-
strual cycle lenght (38). Increases in menstrual cycle length to-
gether with eating a diet rich in phytoestroegens correlate with
a decreased rate of hormone–dependent cancers develop-
ment, including endometrial, ovarian, and breast cancer (39).
Menopausal symptoms
Epidemiological studies show that Asiatic women experience
hot flashes less frequently than the Western women (20% ver-
sus 80%, respectively).
Diet has been included among the different reasons proposed
to explain such proven difference. Indeed, Asian diet is known
to be rich in phytoestrogens and even though only few clinical
trials have been conducted to evaluate the role of these bioac-
tive substances in regulating the menopause symptoms, most
data from randomized studies indicate a significant drop in the
severity and frequency of menopausal symptoms. However,
women given placebos also demonstrated a decline in
menopausal symptoms (40, 41). The variability in frequency
and severity of the hot flashes and the high placebo-response
rate make these clinical trials difficult to interpret and, currently,
they are not sufficient to demonstrate the effectiveness of phy-
toestrogens in reducing menopausal symptoms. However, con-
sidering the lower than expected effectiveness of HRT (22), it
is not surprising that many new studies, planned to show the
benefit in the reduction of menopause symptoms with phytoe-
strogen supplementation, are in progress.
Soy and cognitive function
There is a clear evidence that treatment of postmenopausal
women with mammalian estrogens improves memory and may
alleviate the decline of cognitive function and the risk of de-
mentia (42). A few studies have examined the effect of phytoe-
strogens on cognitive function. Data from a follow-up study of
the cognitive functions showed improvement in pictures recall,
sustained attention and ability to plan tasks, but on the other
side these women did not demonstrate any improvement in
mood or sleepiness, suggesting a specific action on frontal
lobe functions (43). In summary, there are too few studies to
evaluate whether phytoestrogens may exert some effects on
cognitive abilities resulting in a better quality of life in post-
menopausal women.
A nutritional model: soy-foods and bone health
Soy intake is part of the regular diet of the Asian populations.
Observations that soy consuming populations have lower hip
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Table IV - Summary of phytoestrogen clinical studies. 
Clinical endpoints Positive results Total
Maintaining bone density 11 115
Relief menopause symptoms 14 117
Cardiovascular benefit 25 138
Cancer prevention 17 113
Hormon levels/menstrual cycle 12 119
Effect of hormones in men 10 111
Immune system 11 111
Neurological 15 115
Totals 64 105
Totals are less than the sum of the studies since some studies examined
several clinical endpoints.
Modified from Cornwell et al. 2004 (ref. 19).
fracture rate have given rise to the hypothesis that the intake of
soy–proteins and/or soy–derived isoflavonoid phytoestrogens
may be protective for bone health (44). Researchers have long
recognized that Asian women, consuming traditional diet, enjoy
better cardiovascular and bone health than their counterparts
in Western societies. Nutrition epidemiologists believe that this
may partly be the result of the soy rich diet. The scientific inter-
est of isoflavones began with epidemiological studies of elderly
women in Asian countries who consume high levels of
isoflavones from soy products. The studies showed a positive
correlation between a lower prevalence of hip fractures and the
intake of soy–food (45). However, this type of association is in-
conclusive, as Asian women have different hip geometry than
Caucasian women (46). Further epidemiological studies, con-
ducted in Japan and in Hong Kong to directly examine the link-
age between dietary soy–foods intake and lumbar spine bone
mineral density (BMD) in Asian women, showed a significantly
greater BMD in women consuming the highest level of dietary
isoflavones compared to those who consumed the least (47).
These results do not demonstrate how this protective effects of
soy and/or their isoflavones is related to the length of exposure
that, usually, for the majority of Asians is over the entire life
span (48).
Various studies on animal model, using ovariectomized female
rats fed with soy-foods or soy derivatives have shown compa-
rable bone-sparing effects of 17β-estradiol and soy protein iso-
late (49), genistein (50) or daidzein (51).
Clinical trials on the effects of soy isoflavones on bone are
too limited and have shown mixed results (52, 53). Studies
have used both soy protein isolate with isoflavones and iso-
lated isoflavones, but the published clinical studies have been
of short duration with only one 12-months trial. The 6 months
studies demonstrated promising effects of soy protein iso-
lates containing isoflavones on spine BMD in peri- and post-
menopausal women, but they were too short to adequately
evaluate the impact of an intervention on BMD (52). However,
the 12 months trial provided confirmations of the positive ef-
fect of genistein on bone (53), although no consistent
changes in biochemical markers of bone turnover have been
reported. 
None of the studies in both animals and humans have assessed
the effects of soy isoflavones on calcium metabolism. Such infor-
mation is essential in ascertaining the mode of action of
isoflavones on the skeleton. In addition to the estrogenic role of
isoflavones in bone health, it has been also demonstrated that
many soy foods are a good source of calcium and soy proteins
are less calciuric than animal proteins. Although soybeans con-
tain both oxalates and phytates, which are inhibitors of calcium
absorbtion, calcium bioavailability from soy beans has been
shown to be equivalent to that from milk (54). An exception is
represented by calcium-fortified soy beverage from which calci-
um absorption was reported to be 75% of that from cows milk
(55). In comparison to animal proteins, soy proteins contain less
sulfur-containing aminoacids. One study found that subjects con-
suming animal protein-based diets excreted 150 mg of urinary
calcium per day in comparison with about 100 mg of those sub-
jects consuming a soy protein-based diet (56). 
In conclusion, the habitual intake of soy, as traditional Asian
food, appears to be beneficial to bone health, though the effec-
tive or optimal dosage is still unclear. The soy-bone action
could be mediated through its estrogenic or calcium conserving
effects. In addiction, soy intake also contributes to an increase
in high quality protein intake. Therefore, this traditional dietary
practice should be encouraged and preserved in Asian popula-
tions.
Although European countries have no soy consumption tradi-
tion, another plant estrogen group, known as lignans, seems to
have a positive impact on bone health in European countries,
as well as in the vegetarian population. This is due to the rela-
tively high levels of these compounds in certain grains, espe-
cially in rye, as well as in flaxseed that are part of the daily diet
in these populations. Interestingly, there is a striking similarity
between the European vegetarian and Asian-Japanese popula-
tions, exhibiting a lower incidence of osteoporosis compared to
the non-vegetarian populations (57).
A pharmacological model: phytoestrogens and bone health
Most of the studies suggest that phytoestrogens are somewhat
effective in maintaining BMD in postmenopausal women (58-
65). Moreover, recent results from the Women’s Health Initia-
tive Study, showing an unexpected lack of cardioprotective ef-
fects of HRT (22), pushed the research for alternative and nat-
ural strategies for managing and preventing osteoporosis. The
last full review (66) about the dietary phytoestrogens and their
effect on bone justifies the bone-conserving properties of
isoflavones by the following bodies of experimental evidences
showing tight similarities with an experimental pharmacological
model from in vitro studies of cultured bone cells through ani-
mal models of osteoporosis to epidemiological and intervention
studies on humans.
Most of the in vitro studies with human and animal osteoblasts
and osteoblast-like cell-lines have shown that daidzein and
genistein have a stimulatory effect on protein synthesis and on
alkaline phosphatase release (67, 68). This effect is blocked by
the addition of actinomycin or cycloheximide, suggesting that
these isoflavones influence transcriptional or translational
events (66). More recently, genistein has been found to stimu-
late the production of osteoprotegerin (OPG) by human os-
teoblasts, providing a further mechanism for the bone-sparing
effects of soy isoflavones. Besides ER-dependent processes,
genistein and daidzein both suppress osteoclast activity by
several mechanisms, including apoptosis, activation of protein
tyrosine phosphatase, inhibition of cytokines, changes in intra-
cellular Ca++, membrane depolarization and antioxidant activi-
ty, much like many other polyphenols (69, 72). In some cases
the antioxidant effect occurs in the nM range. Furthermore a
positive synergy between phytoestrogens and other antioxi-
dants has been also described (73).
A number of observational and dietary intervention studies con-
firm the general findings from in vitro effects of phytoestrogens
on human bone cells in culture. Thus far, observational or epi-
demiologic studies (74, 75) and dietary intervention studies (76,
81) have shown significant relationships between phytoestro-
gens and surrogate markers of bone turnover such as urinary
calcium, magnesium and phosphorous, hydroxyproline, and col-
lagen cross-links and serum markers including bone specific al-
kaline phosphatase, osteocalcin, insulin-like growth factor I (IGF-
I), and interleukin 6 (Tables Va and Vb). Most of the observation-
al studies have been performed in women living in Countries
where the indigenous population have relatively high phytoestro-
gen intake, mostly related to the soy protein foods.
Conclusions
Since it has now been established that lifestyle and particularly
nutritional habits significantly contribute to the occurrence of
different rates of degenerative disorders, such as cardiovascu-
lar diseases, osteoporosis, cognitive disability, and cancer, in
recent years Eastern and Western governments and industries
have started to invest in the evaluation of the health effects of
phytochemicals contained in the diet. This aspect is becoming
a main feature of preventive medicine since life expectation is
growing in the Western World population. 
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Up to date, it is not still completely clear if the foods rich in
such compounds may really be protective on human health
and, in the event of, at which daily regimen they should be as-
sumed to exert a real pharmacological action. Moreover, non
estrogenic compounds are coexisting with phytoestrogens in
the same plant-derived food and the role that they may play on
both activity and bioavailability of phytoestrogen themselves
has not been elucidated. Since at present industries can pro-
duce extract compounds from this foodstuffs, researchers may
take advantage to plan experimental studies and clinical trials
in which these molecules can be tested in relation to biomark-
ers and other functional parameters connected with human
pathophysiology. Consequently, the possibility of testing the
purified phytochemical compounds, both in in vitro and in vivo
experimental models, may offer the opportunity to corroborate
data obtained from epidemiological studies.
128 Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 123-130
L. Bacciottini et al.
Table Va - Intervention studies with phytoestrogens and bone health in women including findings on BMD and BMC. 
Reference Subjects Intervention Study Findings
(protein type and length BMD or BMC endpoint by DXA
daily isoflavone level) (months)
Dalais et al., Postmenopausal Soy grits 45 g 3 All 3 groups had increased in BMC.
1998 n = 45 Wheat kibble 45 g Soy group 5.2%, Flax group 5.2% and 
Flaxseed 45 g Control group 4.0%
Potter et al., Postmenopausal Casein 40 g/d 6 + 2.2% increase in lumbar spine BMD
1998 n = 66 Soy 40 g/56 mg in soy 90 mg isoflavone group.
Soy 40 g/90 mg The 56 mg isoflavone group unchanged
Ca supplemented No changes in other sites.
Clifton-Bligh et al., Postmenopausal Clover-derived tablets 6 BMD at proximal radio and ulna increased 4.1%
2001 n = 46 28.5, 57 and 85.5 mg with 57 mg/d and 3.0% with 85.5 mg/d.The 
18.5 mg/d remained unchanged. No increase in
endometrial thickness was seen in any group.
Anderson et al., Young healthy Isoflavone-rich diet, 12 No effect of soy diet on BMD or BMC in healthy, 
2002 Adult women 90 mg, compared menstruating women
n = 27, age 21-25 y with control diet
Modified from Setchell KDR et al., 2003 (68).
BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; uDpy, urinary deoxypiridinoline; PTH. parathyroid hormone;
BAP, bone-specific alkaline phosphatase; IGF-I, insulin-like growth factor; ERT, estrogen replacement therapy; NTx, crosslinked N-telopeptides of type I colla-
gen; OC osteocalcin; Ca, calcium; ALP, alkaline phosphatase.
Table Vb - Intervention studies with phytoestrogens and bone health in women including findings on bone markers.
Reference Subjects Intervention Study Findings
(protein type and length Bone markers endpoints
daily isoflavone level)
Wong, 2000 Postmenopausal Soy isoflavones 6 wk Resorption markers: uDpy -7 ± 41%,
n = 6 160 mg/d Urinary Ca concentration -12 ± 46%
Open pilot study s PTH +33 ± 60%
Mean age 55.4 y Urinary Ca excretion -5 ± 29%
Bone formation markers: sOC 9 ± 15%
Serum BAP -16 ± 23%, IGF-I -8 ± 27%
Changes are of similar magnitude to those 
reported for ERT.
Scheiber, 2001 Postmenopausal n = 42 Whole soy foods, 60 mg 3 mo Resorption markers: serum ALP unchanged,
Mean age 55.5 y isoflavones/d urinary NTx decreased 13.9%
Open pilot study No Ca supplementation Formation markers: serum OC increased 10.3%.
Lu et al., 2002 Postmenopausal n = 12 Soy milk 1.08 L/d 4 mo Increase in uDpy 21% and serum BAP 18%,
Age range: 49-66 y ≈ 112 mg isoflavones increase in OC 34%. Values returned to prediet
level 4 mo after diet. No estrogenic effects on
uterus. No changes in serum levels of PTH, 
follicle-stimulating hormone or estradiol.
Modified from Setchell KDR et al., 2003 (68).
BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; uDpy, urinary deoxypiridinoline; PTH. parathyroid hormone;
BAP, bone-specific alkaline phosphatase; IGF-I, insulin-like growth factor; ERT, estrogen replacement therapy; NTx, crosslinked N-telopeptides of type I colla-
gen; OC osteocalcin; Ca, calcium; ALP, alkaline phosphatase.
Unfortunately, due to the great diversity of phytoestrogen com-
pounds, including different bioavailability, pharmacokinetics,
pharmacological properties and metabolic fates, it is quite com-
plex to define, assess and understand their precise effects on
human health since large and time extended intervention stud-
ies are needed.
Osteoporosis represents one of the human disease models
more largely studied for the potential therapeutic effects of phy-
toestrogens.
Currently, the results from the few studies on bone health are
seductive but too few to draw definitive conclusions. Support-
ing data from in vitro and in vivo studies of models of osteo-
porosis strongly shows bone-sparing effects from dietary phy-
toestrogens. Such data may justify large-scale clinical dietary
intervention studies of phytoestrogens in early future.
Finally, the preliminary data in this field suggest to include phy-
toestrogen rich foods in the health foods sector and push sci-
entists to isolate the active molecules to be used as new poten-
tial drugs. 
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